Robalzotan
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data | |
---|---|
Routes of administration |
Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C18H23FN2O2 |
Molar mass | 318.174 g/mol |
3D model (Jmol) | |
|
|
|
|
NY (what is this?) (verify) |
Robalzotan (NAD-299, AZD-7371) is a selective antagonist at the 5-HT1A receptor.[1] It was shown to completely reverse the autoreceptor-mediated inhibition of serotonin release induced by the administration of selective serotonin reuptake inhibitors like citalopram in rodent studies.[2] It was subsequently investigated by AstraZeneca as a potential antidepressant but like many other 5-HT1A ligands was discontinued.[3] Later on it was researched for other indications such as irritable bowel syndrome but was dropped once again.[4]
See also[edit]
References[edit]
- ^ Jerning E, Svantesson GT, Mohell N (1998). "Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist.". Eur J Pharmacol. 360 (2-3): 219–225. doi:10.1016/S0014-2999(98)00667-0. PMID 9851589.
- ^ Arborelius L, Wallsten C, Ahlenius S, Svensson TH (1999). "The 5-HT(1A) receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing.". Eur J Pharmacol. 382 (2): 133–138. doi:10.1016/S0014-2999(99)00592-0. PMID 10528148.
- ^ Mucke HA. (2000). "Robalzotan AstraZeneca.". Curr Opin Investig Drugs. 1 (2): 236–240. PMID 11249580.
- ^ Drossman DA, Danilewitz M, Naesdal J, Hwang C, Adler J, Silberg DG (October 2008). "Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome". The American Journal of Gastroenterology. 103 (10): 2562–9. doi:10.1111/j.1572-0241.2008.02115.x. PMID 18775020.
5-HT1A agonists | |
---|---|
GABAAR PAMs |
|
α2δ VDCC blockers | |
Antidepressants |
|
Sympatholytics | |
Others |
Drugs for functional gastrointestinal disorders (A03)
|
|||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drugs for functional bowel disorders |
|
||||||||||||||||||||
Belladonna and derivatives (antimuscarinics) |
|
||||||||||||||||||||
Propulsives |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Hidden categories: